• José David Torres-Peña, Luis M Pérez-Belmonte, Francisco Fuentes-Jiménez, Mª Dolores López Carmona, Pablo Pérez-Martinez, José López-Miranda, Francisco Javier Carrasco Sánchez, Juan Antonio Vargas Núñez, Esther Del Corral Beamonte, Jeffrey Oskar Magallanes Gamboa, Andrés González García, Julio González Moraleja, Andrés Cortés Troncoso, Taboada MartínezMaría LuisaMLInternal Medicine Department, Cabueñes Hospital, Gijón, Asturias, Spain., María Del Pilar Del Fidalgo Montero, José Miguel Seguí Ripol, Ricardo Gil Sánchez, Diana Alegre González, Ramon Boixeda, Cortés RodríguezBegoñaBInternal Medicine Department, Alto Guadalquivir Hospital, Andújar, Jaén, Spain., Javier Ena, Gema María García García, Ana Ventura Esteve, José Manuel Ramos Rincón, Ricardo Gómez-Huelgas, and SEMI-COVID-19 Network.
• Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
• Drugs. 2021 Apr 1; 81 (6): 685-695.

BackgroundThe impact of statins on COVID-19 outcomes is important given the high prevalence of their use among individuals at risk for severe COVID-19. Our aim is to assess whether patients receiving chronic statin treatment who are hospitalized with COVID-19 have reduced in-hospital mortality if statin therapy is maintained during hospitalization.MethodsThis work is a cross-sectional, observational, retrospective multicenter study that analyzed 2921 patients who required hospital admission at 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics and COVID-19 disease outcomes between patients receiving chronic statin therapy who maintained this therapy during hospitalization versus those who did not. Propensity score matching was used to match each statin user whose therapy was maintained during hospitalization to a statin user whose therapy was withdrawn during hospitalization.ResultsAfter propensity score matching, continuation of statin therapy was associated with lower all-cause mortality (OR 0.67, 0.54-0.83, p < 0.001); lower incidence of acute kidney injury (AKI) (OR 0.76,0.6-0.97, p = 0.025), acute respiratory distress syndrome (ARDS) (OR 0.78, 0.69- 0.89, p < 0.001), and sepsis (4.82% vs 9.85%, p = 0.008); and less need for invasive mechanical ventilation (IMV) (5.35% vs 8.57, p < 0.001) compared to patients whose statin therapy was withdrawn during hospitalization.ConclusionsPatients previously treated with statins who are hospitalized for COVID-19 and maintain statin therapy during hospitalization have a lower mortality rate than those in whom therapy is withdrawn. In addition, statin therapy was associated with a decreased probability that patients with COVID-19 will develop AKI, ARDS, or sepsis and decreases the need for IMV.

20 keywords...

hide…